AVIR
Income statement / Annual
Last year (2023), Atea Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Atea Pharmaceuticals, Inc.'s net income was -$135.96 M.
See Atea Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$0.00
|
$0.00
|
$351.37 M
|
$48.63 M
|
$0.00
|
$0.00
|
| Cost of Revenue |
$70.09 M |
$260,000.00 |
$29,000.00 |
$19,000.00 |
$17,000.00 |
$17,000.00 |
| Gross Profit |
-$70.09 M |
-$260,000.00 |
$351.34 M |
$48.61 M |
-$17,000.00 |
-$17,000.00 |
| Gross Profit Ratio |
0 |
0 |
1 |
1 |
0 |
0 |
| Research and Development
Expenses |
$132.84 M
|
$81.94 M
|
$167.21 M
|
$38.02 M
|
$10.17 M
|
$6.68 M
|
| General & Administrative
Expenses |
$49.92 M
|
$48.71 M
|
$45.79 M
|
$21.64 M
|
$4.44 M
|
$2.80 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$49.92 M
|
$48.71 M
|
$45.79 M
|
$21.64 M
|
$4.44 M
|
$2.80 M
|
| Other Expenses |
-$88.69 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$94.07 M |
$130.65 M |
$212.99 M |
$59.66 M |
$14.61 M |
$9.48 M |
| Cost And Expenses |
$164.16 M |
$130.65 M |
$212.99 M |
$59.66 M |
$14.61 M |
$9.48 M |
| Interest Income |
$29.22 M |
$11.15 M |
$213,000.00 |
$83,000.00 |
$574,000.00 |
$413,000.00 |
| Interest Expense |
$0.00 |
$11.15 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$416,000.00
|
$260,000.00
|
$29,000.00
|
$19,000.00
|
$17,000.00
|
$17,000.00
|
| EBITDA |
-$119.59 M
|
-$110.84 M
|
$138.41 M
|
-$11.01 M
|
-$14.59 M
|
-$9.46 M
|
| EBITDA Ratio |
0 |
0 |
0.39 |
-0.23 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0.39
|
-0.23
|
0
|
0
|
| Total Other
Income/Expenses Net |
$29.22 M
|
$11.15 M
|
$213,000.00
|
$83,000.00
|
$574,000.00
|
$413,000.00
|
| Income Before Tax |
-$134.94 M |
-$119.50 M |
$138.59 M |
-$10.95 M |
-$14.03 M |
-$9.06 M |
| Income Before Tax Ratio
|
0
|
0
|
0.39
|
-0.23
|
0
|
0
|
| Income Tax Expense |
$1.02 M |
-$3.59 M |
$17.40 M |
-$83,000.00 |
-$574,000.00 |
$413,000.00 |
| Net Income |
-$135.96 M |
-$115.91 M |
$121.19 M |
-$10.86 M |
-$13.46 M |
-$9.06 M |
| Net Income Ratio |
0 |
0 |
0.34 |
-0.22 |
0 |
0 |
| EPS |
-1.63 |
-1.39 |
1.46 |
-0.13 |
-0.16 |
-0.19 |
| EPS Diluted |
-1.63 |
-1.39 |
1.37 |
-0.13 |
-0.16 |
-0.19 |
| Weighted Average Shares
Out |
$83.39 M
|
$83.25 M
|
$82.82 M
|
$82.44 M
|
$82.62 M
|
$47.29 M
|
| Weighted Average Shares
Out Diluted |
$83.39 M
|
$83.25 M
|
$88.25 M
|
$82.44 M
|
$82.62 M
|
$47.29 M
|
| Link |
|
|
|
|
|
|
